Terms: = Brain cancer AND PDCD1, CD279, PD-1, PD1, SLEB2, hPD-1, hPD-l, hSLE1 AND Prognosis
169 results:
1. Multi-cohort comprehensive analysis unveiling the clinical value and therapeutic effect of
Liu Z; Yang L; Xie Z; Yu H; Gu T; Shi D; Cai N; Zhuo S
Oncol Res; 2024; 32(5):965-981. PubMed ID: 38686055
[TBL] [Abstract] [Full Text] [Related]
2. Inhibition of autophagy-related protein 7 enhances anti-tumor immune response and improves efficacy of immune checkpoint blockade in microsatellite instability colorectal cancer.
Zhang W; Chen L; Liu J; Chen B; Shi H; Chen H; Qi H; Wu Z; Mao X; Wang X; Huang Y; Li J; Yu Z; Zhong M; Wang T; Li Q
J Exp Clin Cancer Res; 2024 Apr; 43(1):114. PubMed ID: 38627815
[TBL] [Abstract] [Full Text] [Related]
3. Predictive Value of NLR and PLR in Driver-Gene-Negative Advanced Non-Small Cell Lung cancer Treated with pd-1/PD-L1 Inhibitors: A Single Institutional Cohort Study.
Yuan Q; Xu C; Wang W; Zhang Q
Technol Cancer Res Treat; 2024; 23():15330338241246651. PubMed ID: 38613344
[TBL] [Abstract] [Full Text] [Related]
4. [Interest of focal radiotherapy in case of oligoprogression under immunotherapy in the treatment of metastatic non-small cell lung cancer].
Gagé A; Pereira B; Belliere A; Janicot H; Jeannin G; Bourrachot C; Durand M; Rolland-Debord C; Merle P
Bull Cancer; 2023 Dec; 110(12):1234-1243. PubMed ID: 38445648
[TBL] [Abstract] [Full Text] [Related]
5. Spatial and temporal heterogeneity of tumor immune microenvironment between primary tumor and brain metastases in NSCLC.
Liu JS; Cai YX; He YZ; Xu J; Tian SF; Li ZQ
BMC Cancer; 2024 Jan; 24(1):123. PubMed ID: 38267913
[TBL] [Abstract] [Full Text] [Related]
6. TCCIA: a comprehensive resource for exploring CircRNA in cancer immunotherapy.
Wang S; Xiong Y; Zhang Y; Wang H; Chen M; Li J; Luo P; Luo YH; Hecht M; Frey B; Gaipl U; Li X; Zhao Q; Ma H; Zhou JG
J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38212124
[TBL] [Abstract] [Full Text] [Related]
7. [Immunotherapy against gliomas].
Sahm K; Weiss T
Nervenarzt; 2024 Feb; 95(2):111-116. PubMed ID: 38169045
[TBL] [Abstract] [Full Text] [Related]
8. Case report: Leptomeningeal metastasis of advanced nasopharyngeal carcinoma treated with chemoimmunotherapy.
Shi M; Sun D; Ma X; Liu J; Zhang Y; Liu T; Chen X; Mo S; Zhao Y; Zhang L
Hum Vaccin Immunother; 2023 Dec; 19(3):2294579. PubMed ID: 38111107
[TBL] [Abstract] [Full Text] [Related]
9. APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.
Zhao S; Li Y; Xu J; Shen L
Neurol Res; 2024 Mar; 46(3):227-242. PubMed ID: 38007705
[TBL] [Abstract] [Full Text] [Related]
10. Protein Disulfide Isomerase A2 Is Correlated with Immune Infiltrates and Is a Novel Prognostic Biomarker in Glioma Patients.
Ma ZG; Liu YX; Zou N; Huang Z; Wang M; Li T; Zhou J; Chen LG
Curr Med Sci; 2023 Dec; 43(6):1107-1115. PubMed ID: 37978154
[TBL] [Abstract] [Full Text] [Related]
11. Glioblastoma Immunotherapy: A Systematic Review of the Present Strategies and Prospects for Advancements.
Agosti E; Zeppieri M; De Maria L; Tedeschi C; Fontanella MM; Panciani PP; Ius T
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894718
[TBL] [Abstract] [Full Text] [Related]
12. Immunotherapy and brain metastasis in lung cancer: connecting bench side science to the clinic.
Rios-Hoyo A; Arriola E
Front Immunol; 2023; 14():1221097. PubMed ID: 37876939
[TBL] [Abstract] [Full Text] [Related]
13. Global research trends in immunotherapy for glioma: a comprehensive visualization and bibliometric analysis.
Zhang HY; Yu HY; Zhao GX; Jiang XZ; Gao G; Wei BJ
Front Endocrinol (Lausanne); 2023; 14():1273634. PubMed ID: 37867521
[TBL] [Abstract] [Full Text] [Related]
14. Association of the m
Li Y; Cao J; Wang J; Wu W; Jiang L; Sun X
Cancer; 2024 Feb; 130(3):356-374. PubMed ID: 37861451
[TBL] [Abstract] [Full Text] [Related]
15. Clinical implications of RAB13 expression in pan-cancer based on multi-databases integrative analysis.
Zhang XD; Liu ZY; Luo K; Wang XK; Wang MS; Huang S; Li RF
Sci Rep; 2023 Oct; 13(1):16859. PubMed ID: 37803063
[TBL] [Abstract] [Full Text] [Related]
16. Pulmonary pleomorphic carcinoma treated with pd-1 inhibitor: Two case reports.
Jiang T; Wang H; Xue F; Wu X; Ni M; Wang Y; Chen N; Zhang Y; Zhang G; Fu J; Liu X; Wu Q
Thorac Cancer; 2023 Nov; 14(32):3240-3244. PubMed ID: 37779217
[TBL] [Abstract] [Full Text] [Related]
17. Occult extracranial malignancy after complete remission of pineal mixed germ cell tumors: a rare case report and literature review.
Liu J; Fang L; Qi S; Song Y; Han L
BMC Pediatr; 2023 Sep; 23(1):447. PubMed ID: 37679697
[TBL] [Abstract] [Full Text] [Related]
18. Kunitz-type protease inhibitor TFPI2 remodels stemness and immunosuppressive tumor microenvironment in glioblastoma.
Pang L; Dunterman M; Guo S; Khan F; Liu Y; Taefi E; Bahrami A; Geula C; Hsu WH; Horbinski C; James CD; Chen P
Nat Immunol; 2023 Oct; 24(10):1654-1670. PubMed ID: 37667051
[TBL] [Abstract] [Full Text] [Related]
19. Humanized pd-1 Knock-in Mice Reveal Nivolumab's Inhibitory Effects on Glioblastoma Tumor Progression
Chiang CY; Huang MC; Tsai SC; Hsu FT; Liao TL; Yu JH; Lin TH; Huang HH; Liao PA
In Vivo; 2023; 37(5):1991-2000. PubMed ID: 37652472
[TBL] [Abstract] [Full Text] [Related]
20. Monitoring the Outcomes of Systemic Chemotherapy Including Immune Checkpoint Inhibitor for HER2-Positive Metastatic Gastric cancer by Liquid Biopsy.
Jung SH; Lee CK; Kwon WS; Yun S; Jung M; Kim HS; Chung HC; Chung YJ; Rha SY
Yonsei Med J; 2023 Sep; 64(9):531-540. PubMed ID: 37634629
[TBL] [Abstract] [Full Text] [Related]
[Next]
